Actively Recruiting
Cereboost (American Ginseng Extract) and Brain Function
Led by University of East Anglia · Updated on 2025-12-09
200
Participants Needed
2
Research Sites
56 weeks
Total Duration
On this page
Sponsors
U
University of East Anglia
Lead Sponsor
G
Givaudan France Naturals
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study will assess the immediate, short-term benefits of a single dose of a supplement containing 200mg of Panax quinquefolius (American Ginseng) on cognition (brain function) in healthy young adults. To understand the effect this product may have, the participants will complete a series of questionnaires and cognitive tests (tests of memory and brain function) at set intervals across a 6-hour period. Blood samples will also be collected to assess the impact of the study product on the participants.
CONDITIONS
Official Title
Cereboost (American Ginseng Extract) and Brain Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give written informed consent
- Aged between 18 and 40 years inclusive
- Depression Anxiety and Stress Scale (DASS-21) scores: Depression 9, Anxiety 7, Stress 14
- Willing to avoid alcohol for 24 hours before assessment visits
- Willing to avoid caffeine on the morning of assessment visits
- Non-smoker and non-vaper
- Willing to consume the study product
- Willing to attend study visit in an overnight fasted state after following a low-polyphenol diet for 48 hours
- Fluent in written and spoken English
You will not qualify if you...
- Pregnant, planning to become pregnant, lactating, or breastfeeding
- Food allergies or other issues preventing intake of study products
- Unwilling to consume gelatin from bovine or porcine sources
- Body mass index (BMI) less than 18.5 or greater than 30 kg/m2
- Blood pressure over 140/90 mmHg
- Significant acute or chronic health conditions that pose risk or interfere with study, including:
- Cognitive disorders within past 12 months
- Major neuropsychiatric disorders such as bipolar disorder, schizophrenia, schizotypal personality disorder
- Major neurological conditions
- Gastrointestinal disorders like IBS or IBD
- Attention deficit hyperactivity disorder (ADHD)
- Learning disabilities or difficulties
- Uncorrected vision or hearing impairment
- Current or recent use of medications that may interfere with study, including anti-psychotics, anti-coagulants (including Warfarin), anti-platelets (including Aspirin and Clopidogrel), sedatives, and monoamine oxidase inhibitors (MAOIs)
- Taking dietary supplements and unwilling to stop two weeks before and during the study
- Current or past drug or alcohol abuse
- History of HIV, kidney disease, liver or biliary disorders, cancer, cardiovascular disease, or chronic pulmonary disease
- Planned surgery within two weeks of participation
- Not agreeing to have their GP contacted about participation and screening results
- Participation in other cognitive trials within the last month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Quadram Insitute Clinical Research Facility
Norwich, Norfolk, United Kingdom, NR4 7UQ
Actively Recruiting
2
University of East Anglia
Norwich, Norfolk, United Kingdom, NR4 7UQ
Actively Recruiting
Research Team
D
David Vauzour, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here